Norfolk, VA, June 27, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MoreNorfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MorePresenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...
Read MoreNorfolk, VA, June 1st, 2022 – ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases...
Read MoreInhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma RLS-0071 is ReAlta’s lead dual action complement inhibitor...
Read MoreRLS-0071 is a dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and...
Read MoreRLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy...
Read MorePresenting first-in-human trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product candidate...
Read MoreRLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, June 8,...
Read More